Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE (NASDAQ: BIOL) has launched the Advancing Dentistry Podcast in response to increasing demand for its laser technology. The podcast features interviews with dental experts discussing advanced laser protocols and improving dental care. Hosted by Dr. Stephen John, the series is designed to educate listeners on the benefits of Waterlase and Epic laser technology, with 7 episodes currently available. BIOLASE aims to enhance the standard of dental care through this educational platform, showcasing its commitment to innovation and customer education.
BIOLASE, Inc. (NASDAQ: BIOL) is hosting its inaugural Clinical Excellence Forum on June 10-11, 2022, in Costa Mesa, CA, featuring over 20 leading dental professionals from various specialties. The event aims to enhance the integration of laser technology into dental practice, promoting faster adoption and acceptance of lasers in dentistry worldwide. CEO John Beaver highlighted the importance of this collaboration for advancing dental care standards. The forum will cover training models, communication strategies, and innovative ways to improve patient care with laser technology.
BIOLASE, Inc. (NASDAQ: BIOL) has signed a lease agreement in Foothill Ranch, Lake Forest, California, for a new facility aimed at enhancing its training operations and establishing its first Model Dental Office (MDO). The approximately 7,700 square feet space will support growth and marketing objectives, with construction set to begin immediately and completion expected by the end of 2022. CEO John Beaver emphasized that this expansion aligns with the company's strategy to drive revenue and education around laser dentistry, enabling hands-on training for practitioners.
BIOLASE, a leader in dental lasers, announced its participation in the 2022 LD Micro Invitational investor conference on June 8, 2022, at 3:30 PM PST. CEO John Beaver will present to both live and virtual audiences. The conference runs from June 7-9, 2022, and aims to connect investors with innovative companies. BIOLASE develops and sells laser systems for various dental procedures, boasting over 43,300 systems sold globally to date. For more details, register to watch the presentation online.
BIOLASE (NASDAQ: BIOL) announced the formation of a Clinical Integration Team aimed at enhancing the adoption of its dental lasers across North America. This team comprises experienced dental professionals with 90 years of combined experience. The initiative focuses on providing effective mentorship and training to dental practices, facilitating real-time education, in-office training, and workshops. The move underscores BIOLASE's commitment to customer support and aims to capitalize on the growing demand for laser technology in dentistry.
BIOLASE (NASDAQ: BIOL) announced that CEO John Beaver is continuing the "CEO on the Go" initiative, aiming to gather feedback while promoting minimally invasive dentistry. This initiative involves visiting over 100 dentists globally, with 50 visits already completed as of May 2022. Beaver emphasized that over 70% of recent Waterlase sales were to new customers, showcasing the effectiveness of their education and training investments. BIOLASE is recognized for its patented dental laser technology, aimed at improving patient care and recovery times.
BIOLASE, a leader in dental lasers, announced its participation in the Spring Into Action Best Ideas Virtual Investor Conference from May 17-20, 2022. CEO John Beaver will present on May 17 at 1:00 PM PT. The event includes virtual one-on-one meetings on May 19-20. Interested investors can access the live presentation via BIOLASE's website. BIOLASE specializes in developing laser systems for dental and medical use, boasting over 43,300 laser systems sold in 80 countries.
BIOLASE, a leader in dental lasers, announced on May 16, 2022 that it regained compliance with the Nasdaq minimum bid price requirement.
Following a 1-for-25 reverse stock split on April 28, 2022, BIOLASE maintained a bid price above $1.00 for ten consecutive trading days, fulfilling Nasdaq's criteria. This compliance ensures continued listing on the Nasdaq Capital Market.
BIOLASE, Inc. reported a strong first quarter for 2022, achieving $10.2 million in total revenue, marking a 25% increase year-over-year. U.S. laser sales surged by 43% and consumable sales by 35%, driven by heightened procedures. Gross margin improved to 47%, up 13 percentage points, reflecting sales growth. The company maintained $22 million in cash while projecting $10.5 million for Q2, indicating at least 15% growth. BIOLASE emphasized the potential for further market expansion, with only 7%-8% of U.S. dentists currently utilizing dental lasers.
BIOLASE, Inc. (NASDAQ: BIOL) announced the election of Kenneth P. Yale, D.D.S., J.D. to its Board of Directors, effective April 28, 2022. Dr. Yale's extensive experience in healthcare leadership, including roles at Delta Dental and Aetna, is expected to support BIOLASE's business strategy. The board now has a majority of dentists, which will enhance clinical insights. Chairman Jonathan T. Lord highlighted Dr. Yale's potential contributions to align R&D efforts with market needs. BIOLASE focuses on developing innovative laser systems for dentistry, having sold over 43,300 systems across 80 countries.